Παρακολούθηση
Michael Szarek
Michael Szarek
University of Colorado; SUNY Downstate Health Sciences University
Η διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα downstate.edu - Αρχική σελίδα
Τίτλος
Παρατίθεται από
Παρατίθεται από
Έτος
High-dose atorvastatin after stroke or transient ischemic attack
P Amarenco, J Bogousslavsky, A Callahan, LB Goldstein, M Hennerici, ...
New England Journal of Medicine 355 (6), 549-559, 2006
3980*2006
Alirocumab and cardiovascular outcomes after acute coronary syndrome
GG Schwartz, PG Steg, M Szarek, DL Bhatt, VA Bittner, R Diaz, ...
New England Journal of Medicine 379 (22), 2097-2107, 2018
29542018
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
TR Pedersen, O Faergeman, JJP Kastelein, AG Olsson, MJ Tikkanen, ...
Jama 294 (19), 2437-2445, 2005
23032005
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
P Barter, AM Gotto, JC LaRosa, J Maroni, M Szarek, SM Grundy, ...
New England journal of medicine 357 (13), 1301-1310, 2007
21612007
Sotagliflozin in patients with diabetes and recent worsening heart failure
DL Bhatt, M Szarek, PG Steg, CP Cannon, LA Leiter, DK McGuire, ...
New England journal of medicine 384 (2), 117-128, 2021
16512021
Sotagliflozin in patients with diabetes and chronic kidney disease
DL Bhatt, M Szarek, B Pitt, CP Cannon, LA Leiter, DK McGuire, JB Lewis, ...
New England Journal of Medicine 384 (2), 129-139, 2021
10142021
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
JJP Kastelein, WA Van Der Steeg, I Holme, M Gaffney, NB Cater, P Barter, ...
Circulation 117 (23), 3002-3009, 2008
1009*2008
ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome
GG Schwartz, PG Steg, M Szarek, DL Bhatt, VA Bittner, R Diaz, ...
N Engl J Med 379 (22), 2097-2107, 2018
7022018
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study
S Kinlay, GG Schwartz, AG Olsson, N Rifai, SJ Leslie, WJ Sasiela, ...
Circulation 108 (13), 1560-1566, 2003
5942003
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial
GG Schwartz, L Bessac, LG Berdan, DL Bhatt, V Bittner, R Diaz, ...
American heart journal 168 (5), 682-689. e1, 2014
5802014
Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study
LB Goldstein, P Amarenco, M Szarek, A Callahan III, M Hennerici, ...
Neurology 70 (24_part_2), 2364-2370, 2008
5592008
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in …
P Amarenco, LB Goldstein, M Szarek, H Sillesen, AE Rudolph, ...
Stroke 38 (12), 3198-3204, 2007
4742007
Effect of alirocumab on lipoprotein (a) and cardiovascular risk after acute coronary syndrome
VA Bittner, M Szarek, PE Aylward, DL Bhatt, R Diaz, JM Edelberg, Z Fras, ...
Journal of the American College of Cardiology 75 (2), 133-144, 2020
423*2020
LXR/ApoE activation restricts innate immune suppression in cancer
MF Tavazoie, I Pollack, R Tanqueco, BN Ostendorf, BS Reis, ...
Cell 172 (4), 825-840. e18, 2018
4042018
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in …
S Tsimikas, JL Witztum, ER Miller, WJ Sasiela, M Szarek, AG Olsson, ...
Circulation 110 (11), 1406-1412, 2004
3552004
Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients
CB Newman, G Palmer, H Silbershatz, M Szarek
The American journal of cardiology 92 (6), 670-676, 2003
3052003
Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients
C Newman, J Tsai, M Szarek, D Luo, E Gibson
The American journal of cardiology 97 (1), 61-67, 2006
2892006
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY …
KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ...
The lancet Diabetes & endocrinology 7 (8), 618-628, 2019
2742019
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial
AG Olsson, GG Schwartz, M Szarek, WJ Sasiela, MD Ezekowitz, P Ganz, ...
European heart journal 26 (9), 890-896, 2005
2692005
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
AE Frankel, JH Woo, C Ahn, N Pemmaraju, BC Medeiros, HE Carraway, ...
Blood, The Journal of the American Society of Hematology 124 (3), 385-392, 2014
2442014
Δεν είναι δυνατή η εκτέλεση της ενέργειας από το σύστημα αυτή τη στιγμή. Προσπαθήστε ξανά αργότερα.
Άρθρα 1–20